B+
Bull case
25%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
VMD
Viemed HealthcareBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Record revenue, renewed ventilation growth, rapid PAP and resupply expansion, and $15.9 million of quarterly operating cash flow indicate that Viemed can grow under the revised CMS framework while shifting toward less capital-intensive revenue [#SEC-8K-2026-08-03].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
A director and chief medical officer sold 10,000 shares for $117,200 on June 25, 2026; the isolated transaction is not evidence of deteriorating operations but merits monitoring [#SEC-FORM4-2026-06-26].
Momentum
64
Value
69
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.00 · Bull $12.50 · Bear $6.75Analysis 2026-09-19; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.50
Why
Momentum64 · Δ7d +1.2
Value69 · Δ7d +0.1
Sentiment48 · Δ7d -2.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • A director and chief medical officer sold 10,000 shares for $117,200 on June 25, 2026; the isolated transaction is not evidence of deteriorating operations but merits monitoring [#SEC-FORM4-2026-06-26].
- • Execution under revised CMS qualification, documentation, and utilization requirements remains important to ventilation setup, compliance, and patient retention [#PR-EARNINGS-2026-08-11].
- • Adjusted EBITDA declined 4.0% year over year and full-year EBITDA guidance was reduced despite stronger revenue guidance, creating a margin-quality concern.
Catalyst clock
2026-12-31
FY2026 guidance delivery after mixed Q2 revision
Lead driver: Value · See fundamentals
Momentum
64
8% active weight
Current posture
7d trendFlat
Δ7d
+1.2
Δ21d
+34.9
Value
69
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.4
Sentiment
48
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
-18.1
Why this grade
Composite grade B. Momentum 63.7 / Value 68.7 / Sentiment 48.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-19. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.75
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$373.26M
Beta
1.27
Shares Out
38.09M
P/E (TTM)
21.9
P/S (TTM)
1.08
P/FCF (TTM)
51.26
Rev YoY
+23.9%
EPS YoY
-12.5%
Gross Margin
+56.9%
Op Margin
+8.5%
Net Debt
$2.45M
Current Ratio
1.13
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data